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Scabies is a highly contagious, globally prevalent, parasitic skin infestation caused by Sarcoptes 
scabiei var. hominis, also known as the itch mite. There have been outbreaks not only in the 
developing world, but also in the developed world among refugees and asylum seekers. Once 
infested with scabies mites, symptomatic patients, as well as asymptomatic carriers, quickly spread 
the disease through direct skin-to-skin contact. Typically, symptoms of scabies are characterized 
by an erythematous, papular, pruritic rash associated with burrows. Treatment of scabies involves 
using topical or systemic scabicides and treating secondary bacterial infections, if present. Given the 
prevalence and contagiousness of scabies, measures to prevent its spread are essential. Through 
application of the novel Identify-Isolate-Inform (3I) Tool, emergency medical providers can readily 
identify risk factors for exposure and important symptoms of the disease, thus limiting its spread 
through prompt scabicide therapy; isolate the patient until after treatment; and inform local public health 
authorities and hospital infection prevention, when appropriate. Ultimately, these three actions can 
aid public health in controlling the transmission of scabies cases, thus ensuring the protection of the 
general public from this highly contagious skin infestation. [West J Emerg Med. 2020;21(2)191–198.]
INTRODUCTION
Human scabies is a highly contagious, globally prevalent, 
parasitic skin infestation caused by Sarcoptes scabiei var. 
hominis, also known as the itch mite. This parasite was 
identified in the 1687 by Bonomo and Cestoni using a light 
microscope; however, there is evidence of scabies as far 
back as 1200 BCE.1 The most common symptoms of scabies, 
itching and a skin rash, are caused by a hypersensitivity 
reaction to the proteins and feces of the parasite about four 
to six weeks after infestation. Severe pruritus, especially at 
night, is the earliest and most common symptom of scabies. 
An erythematous, papular, pruritic rash with burrows on the 
hands, wrists, torso, and feet is also common.1 
Scabies continues to be a common dermatological disease 
internationally. A systematic review estimated the prevalence 
of scabies in various countries to be 0.2% to 71%.2 In the 
United Kingdom, a general practice database review for 
scabies estimated prevalence to be 2.2 and 2.8 per 1000 in 
men and women, respectively.3 Studies from Greece and Spain 
conducted in dermatology clinics concluded that scabies is 
encountered in approximately 4% of visits, particularly among 
immigrants and patients with low socioeconomic status.4,5  In 
developing countries the prevalence can be much higher,6-9 
ranging as high as 87% in one study in Thai orphanages.10 
Although prevalence of scabies is low in developed countries, 
public health authorities are challenged to identify and treat 
individuals with scabies promptly to avoid transmission 
amongst close-quartered populations, such as within the 
growing population of asylum seekers and refugees.11,12 
Scabies remains a risk to public health, and it is essential 
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Population Health Research Capsule
What do we already know about this issue?
Scabies is a highly contagious parasitic skin 
infestation with outbreaks in the developed 
world, as well as among at-risk populations in 
the developing world.
What was the research question?
Investigators modified the “Identify, Isolate, 
Inform” (3I) Tool for use in identifying and 
managing scabies.
What was the major finding of the study?
A novel Scabies 3I Tool is created for real-time 
application in emergency department (ED) 
patients.
How does this improve population health?
The Scabies 3I Tool aids ED providers who 
play an essential role in identifying and 
treating scabies effectively to avoid spread of 
the infestation.
that frontline healthcare providers identify potential cases. 
Both under- and over-diagnosis are possible, and each is 
problematic. While missing the diagnosis can lead to both 
ongoing individual patient discomfort as well as rapid 
population spread, over-diagnosis can lead to inappropriate 
individual patient treatment and can create stress on healthcare 
systems with finite resources.
Emergency Department (ED) providers may encounter 
and treat these patients as the first point of contact. After an 
overview of the disease and critical information pertaining to 
transmission and treatment, this article adapts the 3I (Identify- 
Isolate-Inform) Tool to assist frontline providers in the 
identification and management of potential cases of scabies 
presenting to the ED (Figure 1). The 3I Tool was originally 
developed for Ebola virus disease and subsequently modified 
for use in measles, Middle East Respiratory Syndrome 
(MERS), mumps, Zika, hepatitis A, pertussis, and 2019 nCoV 
(COVID-19).13-20 
CLINICAL PRESENTATION
Signs and symptoms of scabies differ depending 
on the time since exposure, degree of infestation, host 
immunocompetency, and coexistence of other skin 
pathologies.  When people are first infested with scabies, 
they usually have no symptoms for 4-6 weeks. Classically, 
an intense nocturnal pruritic rash is the first symptom. The 
rash is typically characterized as erythematous with papules 
and associated burrows. Burrows are described as thin grey 
or brown lines that are approximately 5 mm long. Presence 
of burrows is a classic finding of scabies but uncommonly 
visualized due to skin excoriation or the presence of 
secondary infections. In adults and older children, the rash 
is most commonly found in the volar aspect of the wrists, 
interdigital web spaces, periumbilical area, anterior axillary 
folds, buttocks, and genitalia.21 In infants and those who live 
in tropical areas, the rash can be generalized and may also 
involve the scalp, neck, face, palms, and soles.22
RISK FACTORS
Populations at highest risk for scabies include children, 
the elderly, the immunocompromised, and people in 
congregate living conditions, including refugee camps. 
Scabies is found worldwide and the risk of contracting 
infection is present regardless of gender, race, or 
socioeconomic status; however, higher prevalence of scabies 
has been correlated to tropical and subtropical climates, 
resource-poor countries, and areas with armed conflicts, 
homelessness, crowding, and shared use of clothes, beds, and 
blankets or pillows.2,23-25  
DIAGNOSIS
A presumptive diagnosis of scabies can be made based 
on suggestive clinical features such as nocturnal pruritus, 
history of contact with scabies, and/or typical appearance 
and distribution of skin lesions with the presence of burrows. 
However, achieving a definitive diagnosis depends on 
identification of mites, eggs, or fecal material using light 
microscopy. Lesions should be scraped off using a scalpel.  
With the scalpel, the papule should be scraped multiple times 
to remove the top (Video Example: Scabies skin scraping 
technique). Adding a few drops of mineral oil to the skin 
prior to scraping may help the scraped material to adhere 
to the blade. Most hospital pathology laboratories will 
accept scrapings for microscopic evaluations. The pathology 
protocols for scabies skin scraping methods at two university 
hospitals are provided here for reference: University of Iowa 
and University of Michigan. The characteristic microscopic 
appearance is shown here. Even with ideal technique, 
however, failure to find mites, eggs, or fecal material is 
common and does not rule out the disease.26,27 The sensitivity 
of this approach ranges from 40% to 90% and the specificity 
reaches 100%.26 
Alternatively, the burrow ink test may be used. In this 
method, ink is absorbed by the burrows and will be visible 
as wavy lines (Figure 2).24,25 This method requires a dark felt 
tip washable marker or a fountain pen over the affected area 
and an alcohol swab to clean the surface ink. Any remaining 
dark ink under the skin signifies presence of scabies burrows 
(Figure 2). The sensitivity and specificity for the burrow ink 
test is unable to be calculated based on a French dermatology 
study.26 Nevertheless, for any case with concern for scabies in 
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Figure 1. The Identify, Isolate, Inform (3I) Tool for Scabies.
                  
− Implement contact precautions
− Avoid direct skin-to-skin contact until 8 hours 
after scabicide administration
− Wash clothing and items used in hot water
− Treat close contacts within the preceding month
− Notify household and/or close contacts
− Encourage post-exposure prophylaxis
− For an outbreak, report to local health 
department, if required
− Report Norwegian scabies (given high 
transmissibility) to hospital infection prevention
    Two or more consecutive cases among residents/staff within 4–6 weeks 
ISOLATE 
Direct skin contact
− Person-to-person contact
− Sexual contact
Contact with infested objects
− Furniture/Clothing
− Mites can only survive 3 
days at room temperature
High-risk populations
− Children
− Elderly
− Immunocompromised
Transmission can occur prior 
to any symptoms
INFORM 
Rash characteristics
− Generalized
− Erythematous 
− Papules
− Associated with burrows
− Predilection for
− Volar aspect of wrists
− Interdigital web spaces
− Periumbilical areas
− Intense nocturnal pruritus
 
 
SYMPTOMS 
Identify – Isolate – Inform
Guide to the Emergency Department Evaluation and Management of 
Patients Under Investigation (PUIs) for Scabies
Information Current as of September 22, 2019
IDENTIFY 
Exposure OR Symptoms 
EXPOSURE 
WITHIN 4–6 Weeks   
The Identify-Isolate-Inform Tool was conceived by Dr. Kristi L. Koenig, County of San Diego EMS Medical Director & Professor Emerita, UC 
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Figure 2. Scabies burrow ink test.50
the emergency department, this is a simple test that may help 
diagnose scabies. 
A substitute for the burrow ink test is the tetracycline 
fluorescence test, where tetracycline is used instead of ink.28,29 
This method allows for colorless identification of the burrows. 
Similar to the ink, the topical tetracycline solution is applied 
over an affected area, and is wiped with alcohol to remove any 
excess solution on the surface. Then a Wood’s lamp is used to 
visualize the tetracycline that tracked into the burrows.28 
Other scabies diagnostic techniques unlikely to be used 
in the emergency department include video dermatoscopy, 
polymerase chain reaction (PCR) and enzyme-linked 
immunosorbent assays (ELISA), and IgE antibody testing. 
Video dermatoscopy is especially useful in cases with atypical 
distribution or appearance of the lesions.30 Serological tests 
are emerging for both diagnosis and monitoring of treatment 
efficacy. One study showed that real-time PCR and ELISA 
tests are useful for monitoring treatment efficacy.31 Another 
study reported a 100% sensitivity and a specificity of 93% 
using IgE antibody against Sarcoptes scabiei.32
COMPLICATIONS AND SPECIAL POPULATIONS
Secondary bacterial infections can develop in persons 
infested with scabies, particularly since the rash is typically 
intensely pruritic and scratching compromises the skin barrier 
and may introduce bacteria, particularly in patients with poor 
fingernail hygiene. Streptococcus or staphylococcus infections 
can cause impetigo, paronychia, cellulitis, or abscesses.33 
Sequelae of these bacterial infections include bacteremia 
leading to sepsis, acute post-streptococcal glomerulonephritis, 
and rheumatic heart disease.22,33 
The most vulnerable populations to scabies infestations 
are young children, the elderly, and the immunocompromised. 
These populations are especially susceptible to secondary 
complications of infestation. Given transmission is favored in 
conditions of crowding and poor sanitation, outbreaks have 
been seen in refugee camps and asylum seeker shelters.12 
Crusted scabies, also known as Norwegian scabies, is 
particularly serious with a high mortality rate from bacterial 
sepsis.34 Caused by a hyperinfestation of the scabies mites, 
crusted scabies is characterized by development of a severe 
inflammatory response and hyperkeratosis (thickened skin 
crusts).35 Any skin area might be affected, but commonly 
affected regions include the scalp, hands, and feet. Crusts 
are malodorous and nails are thickened and discolored. Most 
cases of the crusted variant are linked to immunocompromised 
hosts; however, cases of crusted scabies have occurred without 
identifiable risk factors.35 From a public health perspective, 
patients with crusted scabies are highly infectious and, 
given they carry a significant number of mites, they can 
be the primary source of a community scabies outbreak. 
Furthermore, crusted scabies is difficult to manage, often 
requiring multiple treatments.35 
TRANSMISSION AND PERSONAL PROTECTIVE 
EQUIPMENT
Human scabies is a parasitic skin infection caused by 
penetration of the ectoparasitic mite Sarcoptes scabiei var. 
hominis into the epidermis. The lifecycle begins with a female 
mite laying eggs in the skin burrows. These larvae hatch, create 
new burrows, and then mature, mate and repeat this cycle.1 
Once infested with scabies mites, symptomatic patients as well 
as asymptomatic carriers can easily spread the disease.1,36
Commonly, transmission occurs from person to person via 
direct skin contact, including by sexual contact. Because of 
the asymptomatic period following infestation, transmission 
can occur prior to symptom onset.1 In addition, fomite 
transmission through infested objects such as furniture and 
clothing is possible, especially with the crusted variant of 
scabies.1,36 Outside the human body and at room temperature 
with normal humidity, mites can only survive up to 3 days, 
whereas they are able to live up to 60 days inside human 
skin.1,36 Lower temperatures and higher humidity prolong 
survival of the mite off the host.23
To prevent transmission within healthcare facilities, 
patients should be in contact isolation until 8 hours after 
treatment.36 Personal protective equipment for healthcare 
workers treating patients with scabies includes the following: 
gowns, gloves, and shoe covers.36 Proper use of infection 
control measures including handwashing and avoiding skin-
to-skin contact should also be used when handling patients 
with potential scabies infestations.
DIFFERENTIAL DIAGNOSIS
The common manifestations of scaling and excoriation 
can impair skin visualization, making the differential 
diagnosis very broad. Clinicians should consider papular 
urticaria, secondary syphilis, folliculitis, contact dermatitis, 
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Medication Dosing Timing Variation for Norwegian scabies
Permethrin cream 5% Apply topically entire body Wash off after 8-14 hours Repeated daily for 7 days then twice weekly until 
discharge or cure* 
*Recommended combination therapy with ivermectin
Ivermectin 200 mcg/kg/dose orally 2 doses 1 week apart 3, 5 or 7 doses depending on severity
3 dose regimen: days 1, 2, 8
5 dose regimen: days 1, 2, 8, 9, 15#
7 dose regimen: days 1, 2, 8, 9, 15, 22, 29
#Recommended combination therapy with permethrin
Sulfur ointment 
(5%-10%)
Apply topically entire body Wash off after 24 hours
Repeat for 3 doses
Not recommended
Table. Medication dosing and timing regimens for scabies with variation for Norwegian (crusted) scabies.
Mcg/kg/dose, micrograms per kilogram per dose.
atopic dermatitis, psoriasis, seborrhea, pityriasis rosea, lichen 
planus, and dermatitis herpetiformis as possible diagnoses.
TREATMENT
Treatment options depend on whether scabies lesions are 
classic or crusted on clinical presentation (Table). In general, 
medications consist of a scabicide that can be applied topically 
or taken orally. For classic scabies, topical permethrin or oral 
ivermectin are considered first-line treatments.23 Dosing 
regimens are included in the table. Although high-quality trials 
comparing medications for the treatment of scabies are 
lacking, a Cochrane systematic review concluded that 
permethrin is more effective than ivermectin.37 A more recent 
2018 systematic review, however, concluded that both 
ivermectin and permethrin have similar efficacy.38 
When used as directed, topical permethrin 5% has high 
cure rates, approaching 90% in randomized trials.39 Permethrin 
is applied topically in patients older than 2 months of age from 
the neck to the soles of the feet and washed off after 8 to 14 
hours. Considering that scabies can also affect the face, scalp 
and neck in infants and young children, topical application 
should be extended to these areas.36,40 Repeating the topical 
permethrin treatment one or two weeks after the first treatment 
is necessary in severe cases.36 Oral ivermectin is an alternate 
therapy that may be used if topical treatment fails; however, 
its safety in pregnant women and children weighing less than 
15 kg has not been established.34,46,37,41-43
For crusted scabies, both an oral and a topical scabicide 
should be administered concurrently (Table).15,19,37 Ivermectin 
use has also been described for scabies control in endemic 
areas or outbreaks where topical scabicide use may be 
difficult.12 A randomized controlled trial examining mass 
administration of ivermectin for management of scabies 
concluded a reduction in prevalence from 32.1% to 1.9% in 
the ivermectin group compared to a reduction from 41.7% to 
15.8% in permethrin-treated controls.44 
Other topical agents such as sulfur, benzyl benzoate, 
crotamiton, and lindane are also options if first-line treatments 
fail.  Topical sulfur is considered safe when used to treat 
infants younger than 2 months of age and pregnant 
women.36,40,41 In addition to scabicides, treatment of secondary 
bacterial infections such as pyoderma or impetigo, if present, 
is indicated via administration of appropriate systemic 
antibiotics.36 Advising patients and parents of young patients 
to keep fingernails short and clean can assist with preventing 
secondary infections.
Patients treated for scabies may have persistent pruritus 
for up to 4 weeks. Many patients return to the ED with 
concerns of treatment failure or reinfestation. These persistent 
symptoms do not necessarily indicate treatment failure. 
Symptomatic treatment and reassurance are often the only 
necessary management. Symptoms that persist or worsen 
beyond 2 to 4 weeks, especially if the rash worsens or new 
burrows appear, should trigger the physician to consider other 
causes such as incorrect diagnosis, treatment failure due to 
resistance or incorrect application, secondary infections, and/
or reinfestation.45 
PREVENTION
To eradicate and prevent reinfestation of the scabies mites, 
close contacts (within the previous 30 days) should be treated 
simultaneously. Additionally, items used by patients and close 
contacts in the preceding several days such as clothing and 
linens should be washed and dried at high temperatures 
(≥60°C), dry-cleaned, or placed in a plastic bag for at least 72 
hours if unable to launder.36,46 Another aspect of controlling 
this disease is avoidance of direct skin-to-skin contact with 
suspected or confirmed cases of scabies until 8 hours after 
treatment.36 Treatment failures occur in some instances due to 
improper or inadequate application of the medications, 
reinfestation secondary to mishandling of clothes and bed 
linens, undertreatment of close contacts, and resistance to 
some medications, such as lindane.34,35,37,41-43,47 Prevention and 
control of crusted (Norwegian) scabies is more complicated 
given that brief skin-to-skin contact can spread the infection. 
In these cases, numerous contacts may need treatment to 
prevent a large-scale outbreak.35,41 In communities with a high 
prevalence of scabies, mass drug administration of scabicides 
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has been used for effective control. This may be a strategy for 
large outbreaks; however, local health authorities should be 
consulted prior to instituting this approach.48 
DISPOSITION
Hospitalization is not recommended in patients with 
scabies unless they have other indications, such as crusted 
(Norwegian) scabies or severe secondary infections.  Follow-
up care 2-4 weeks after treatment should be arranged to 
assess for medication failure as well as reinfestation.38 Based 
on suggested general guidelines by the Centers for Disease 
Control and Prevention, patients with scabies may return 
to work or school 1 day after starting treatment and prior to 
follow-up.36 Healthcare providers with scabies who deliver 
direct hands-on care to patients and remain symptomatic 
after beginning treatment may return to work if they observe 
standard precautions, including the use of disposable gloves, 
until they are sure they are no longer infested.36  
IDENTIFY-ISOLATE-INFORM (3I)
The Identify-Isolate-Inform (3I) Tool was conceived 
during the 2014 Ebola virus disease outbreak and later 
modified for application to the ED evaluation and 
management of patients with other communicable diseases.14-20 
The novel modification of this tool presented here can be 
applied for ED evaluation and management of a patient 
under investigation for scabies. The Scabies 3I Tool is an 
algorithm that begins with identifying suspected cases based 
on symptoms, exposure history, and testing as needed. History 
of exposure is important as patients can transmit scabies prior 
to symptom onset. Identification of close contacts is also an 
important step in controlling the spread of the infestation. 
To prevent transmission within healthcare facilities, 
patients should be isolated in contact isolation until 8 hours 
after treatment.36 Personal protective equipment for healthcare 
workers treating patients with scabies includes the following 
protective garments: gowns, gloves, and shoe covers.36 Proper 
use of infection control measures including avoiding skin-
to-skin contact and handwashing should be observed when 
handling patients with potential scabies infestations.36 
Given the transmissibility of this disease and potential 
outbreaks that may threaten public health, ED staff should 
immediately inform the local health authority in cases of 
outbreak, defined as two or more consecutive cases of 
scabies among residents/staff within 4-6 weeks.49 Timely 
notification of an outbreak is especially important in cases of 
scabies identified from healthcare facilities, shelters, or other 
communities where the disease could rapidly spread, including 
refugee and migrant shelters. In an online review of 20 
hospital policies across the United States, no hospital required 
informing hospital infection control of scabies cases; however, 
individual hospital policies may vary both within the U.S. and 
internationally. Therefore, it is important to know and follow 
local hospital policies on scabies reporting. Additionally, cases 
of crusted (Norwegian) scabies should be isolated promptly 
and all close contacts should be informed and treated, given 
its high transmission rate.35,41 Using this 3I Identify-Isolate-
Inform Tool, healthcare providers can be more prepared to 
detect and manage potential scabies cases.
CONCLUSION
Prompt recognition of transmittable diseases, like scabies, 
by emergency healthcare workers is needed to mitigate spread. 
Scabies can be challenging to diagnose, and both under- and 
over-diagnosis of scabies have negative health and resource 
consequences. The novel Scabies Identify-Isolate-Inform (3I) 
Tool can aid ED staff in readily recognizing key risk factors 
for exposure and characteristic symptoms of the disease, 
thereby triggering implementation of appropriate isolation 
protocols, and notification of hospital and public health 
agencies, as appropriate.
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